Harrison Seth Loring 4

What Happened

• Seth Loring, a director of Stoke Therapeutics (STOK), reported a series of gift (code G) transactions on July 16, 2026 totaling 151,595 shares. Each transaction is reported at $0.00 (no consideration) and listed as derivative securities. The filing shows paired disposals and acquisitions, resulting in a net change of 0 shares in beneficial ownership.

Key Details

• Transaction date: July 16, 2026; Form 4 filed July 17, 2026 (timely).
• Total shares involved: 151,595 shares across multiple gift entries; all reported at $0.00.
• Net effect: No net increase or decrease in reported beneficial ownership (disposals equal acquisitions).
• Relevant footnotes: F1 — gifts reported for no consideration and exempt from short‑swing profit liability under Rule 16b‑5; F3 — some securities are held directly by the East Pillar 2026 Irrevocable Trust for which the reporting person is a board member and beneficiary (indicating transfers involving a trust).
• Filing timeliness: Filed promptly (next business day), not marked late.

Context

• Code G indicates gifts — these are transfers for no consideration and do not necessarily signal buy/sell sentiment by the insider. Because entries are labeled as derivative and tied to a trust (per footnote), this appears to reflect transfers of ownership/beneficial interest rather than open‑market trading.